ATED Therapeutics

Company Overview

Snapshot

Founded in March 2022, ATED Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing diagnostics and therapeutics for central nervous system diseases.

Business overview

ATED Therapeutics is a Health Tech & Life Sciences company focused on developing diagnostics and therapeutics for Parkinson’s disease and other central nervous system diseases. Its core product is an investigational transfer RNA fragment blood test designed to detect Parkinson’s earlier, monitor disease progression, and quantify response to deep brain stimulation. The company is also developing two disease-modifying Parkinson’s drug candidates, operating within the Medical Devices and Diagnostics Devices sectors.

Company Intelligence Q&A

What is ATED Therapeutics' primary focus?

ATED Therapeutics primarily focuses on developing diagnostics and therapeutics for Parkinson’s disease and other central nervous system diseases.

What is the company's lead product?

The company's lead product is an investigational transfer RNA fragment blood test intended to help detect Parkinson’s earlier, monitor disease progression, and quantify response to deep brain stimulation.

What other developments is ATED Therapeutics pursuing?

ATED Therapeutics is also developing two disease-modifying Parkinson’s drug candidates.

When was ATED Therapeutics founded?

ATED Therapeutics was founded in March 2022.

What is the current product stage for ATED Therapeutics?

ATED Therapeutics is currently in the R&D product stage, developing its investigational transfer RNA fragment blood test and two disease-modifying Parkinson’s drug candidates.